Last reviewed · How we verify
NCT05508438
To Evaluate the Efficacy and Safety of the Transfemoral Mitral Valve Repair System in the Treatment of Patients With Moderately Severe and Severe Functional Mitral Regurgitation(FMR) Who Remained Clinically Symptomatic After Guideline-directed Medical Treatment
NA trial testing Transfemoral mitral-valve repair in Mitral Valve Insufficiency in 140 participants. Not yet recruiting.
30 December 2023
Quick facts
| Lead sponsor | Pan Xiangbin |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 140 |
| Start date | 30 August 2022 |
| Primary completion | 30 December 2023 |
| Estimated completion | 30 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Transfemoral mitral-valve repair
Conditions studied
- Mitral Valve Insufficiency — all drugs for Mitral Valve Insufficiency →
Sponsor
Pan Xiangbin
Who can join
18 and older, any sex, with Mitral Valve Insufficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To confirm the effectiveness and safety of the transcatheter mitral valve repair system for the treatment of chronic moderate to severe (3+) or severe (4+) functional mitral regurgitation (FMR) who remained clinically symptomatic after guideline-directed medical treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
TEERAI-Pre: A Multiview Artificial Intelligence Model for Preoperative Assessment of Transcatheter Edge-to-Edge Mitral Valve Repair Using Multiview, Multimodal Echocardiography.
Li H, Chen Y, Zhang J, Guo Y, et al · · 2026 · PMID 41614293 · DOI 10.1161/jaha.125.044333
Verify or expand the search:
- PubMed search for NCT05508438
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mitral Valve Insufficiency
Currently open trials in the same condition.
- NCT06757049 — Clinical Outcomes of Edwards Lifesciences MITRIS RESLILA Mitral Valve in the Asian Population · recruiting
- NCT06235385 — European Association of Cardiovascular Imaging Multiple and Mixed Valvular Disease Study · recruiting
- NCT05927441 — DragonFly EU Pivotal Study · NA · recruiting
- NCT04343313 — The Half Moon Transcatheter Mitral Valve Repair (TMVr) Pilot Study · NA · recruiting
- NCT04153292 — The ENCIRCLE Trial · NA · recruiting
Other Pan Xiangbin trials
Trials by the same sponsor.
- NCT07087379 — Perioperative Intensive Statin Therapy for Neuroprotection in TAVR（PISTNT） · Phase 4 · not yet recruiting
- NCT07030062 — Echocardiography Guided TAVR (Echo TAVR) · recruiting
- NCT06684171 — Comparison of Transcatheter Edge-to-edge Repair Using Echo Only with Echo Combined with X Ray for Mitral Regurgitation ( · NA · recruiting
- NCT06136429 — A Prospective, Multicenter, Single-arm Study to Evaluate a Transcatheter Aortic Valve System Safety and Efficacy for the · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05508438 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pan Xiangbin
- Last refreshed: 19 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05508438.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing